Literature DB >> 33293403

Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder.

Hiroshi Nishiwaki1, Tomonari Hamaguchi1, Mikako Ito1, Tomohiro Ishida2, Tetsuya Maeda3, Kenichi Kashihara4, Yoshio Tsuboi5, Jun Ueyama2, Teppei Shimamura6, Hiroshi Mori7, Ken Kurokawa7, Masahisa Katsuno8, Masaaki Hirayama9, Kinji Ohno10.   

Abstract

Gut dysbiosis has been repeatedly reported in Parkinson's disease (PD) but only once in idiopathic rapid-eye-movement sleep behavior disorder (iRBD) from Germany. Abnormal aggregation of α-synuclein fibrils causing PD possibly starts from the intestine, although this is still currently under debate. iRBD patients frequently develop PD. Early-stage gut dysbiosis that is causally associated with PD is thus expected to be observed in iRBD. We analyzed gut microbiota in 26 iRBD patients and 137 controls by 16S rRNA sequencing (16S rRNA-seq). Our iRBD data set was meta-analyzed with the German iRBD data set and was compared with gut microbiota in 223 PD patients. Unsupervised clustering of gut microbiota by LIGER, a topic model-based tool for single-cell RNA sequencing (RNA-seq) analysis, revealed four enterotypes in controls, iRBD, and PD. Short-chain fatty acid (SCFA)-producing bacteria were conserved in an enterotype observed in controls and iRBD, whereas they were less conserved in enterotypes observed in PD. Genus Akkermansia and family Akkermansiaceae were consistently increased in both iRBD in two countries and PD in five countries. Short-chain fatty acid (SCFA)-producing bacteria were not significantly decreased in iRBD in two countries. In contrast, we previously reported that recognized or putative SCFA-producing genera Faecalibacterium, Roseburia, and Lachnospiraceae ND3007 group were consistently decreased in PD in five countries. In α-synucleinopathy, increase of mucin-layer-degrading genus Akkermansia is observed at the stage of iRBD, whereas decrease of SCFA-producing genera becomes obvious with development of PD.IMPORTANCE Twenty studies on gut microbiota in PD have been reported, whereas only one study has been reported on iRBD from Germany. iRBD has the highest likelihood ratio to develop PD. Our meta-analysis of iRBD in Japan and Germany revealed increased mucin-layer-degrading genus Akkermansia in iRBD. Genus Akkermansia may increase the intestinal permeability, as we previously observed in PD patients, and may make the intestinal neural plexus exposed to oxidative stress, which can lead to abnormal aggregation of prion-like α-synuclein fibrils in the intestine. In contrast to PD, SCFA-producing bacteria were not decreased in iRBD. As SCFA induces regulatory T (Treg) cells, a decrease of SCFA-producing bacteria may be a prerequisite for the development of PD. We propose that prebiotic and/or probiotic therapeutic strategies to increase the intestinal mucin layer and to increase intestinal SCFA potentially retard the development of iRBD and PD.
Copyright © 2020 Nishiwaki et al.

Entities:  

Keywords:  Parkinson’s disease; gut microbiota; meta-analysis; rapid-eye-movement behavior disorder; topic model

Year:  2020        PMID: 33293403      PMCID: PMC7771407          DOI: 10.1128/mSystems.00797-20

Source DB:  PubMed          Journal:  mSystems        ISSN: 2379-5077            Impact factor:   6.496


  91 in total

1.  Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients.

Authors:  C Ullrich; R Mlekusch; A Kuschnig; J Marksteiner; C Humpel
Journal:  Curr Alzheimer Res       Date:  2010-09       Impact factor: 3.498

2.  Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.

Authors:  Sorabh Sharma; Rajeev Taliyan; Sumel Singh
Journal:  Behav Brain Res       Date:  2015-06-03       Impact factor: 3.332

3.  Freeze-drying enables homogeneous and stable sample preparation for determination of fecal short-chain fatty acids.

Authors:  Jun Ueyama; Masaya Oda; Masaaki Hirayama; Kuniyo Sugitate; Norihiro Sakui; Risa Hamada; Mikako Ito; Isao Saito; Kinji Ohno
Journal:  Anal Biochem       Date:  2019-11-18       Impact factor: 3.365

4.  Age, Gender, Comorbidity, and the MDS-UPDRS: Results from a Population-Based Study.

Authors:  Mark R Keezer; Christina Wolfson; Ronald B Postuma
Journal:  Neuroepidemiology       Date:  2016-03-12       Impact factor: 3.282

5.  Pathogenic lysosomal depletion in Parkinson's disease.

Authors:  Benjamin Dehay; Jordi Bové; Natalia Rodríguez-Muela; Celine Perier; Ariadna Recasens; Patricia Boya; Miquel Vila
Journal:  J Neurosci       Date:  2010-09-15       Impact factor: 6.167

Review 6.  Sleep and neurological autoimmune diseases.

Authors:  Alex Iranzo
Journal:  Neuropsychopharmacology       Date:  2019-07-14       Impact factor: 7.853

7.  Gut microbiota are related to Parkinson's disease and clinical phenotype.

Authors:  Filip Scheperjans; Velma Aho; Pedro A B Pereira; Kaisa Koskinen; Lars Paulin; Eero Pekkonen; Elena Haapaniemi; Seppo Kaakkola; Johanna Eerola-Rautio; Marjatta Pohja; Esko Kinnunen; Kari Murros; Petri Auvinen
Journal:  Mov Disord       Date:  2014-12-05       Impact factor: 10.338

8.  Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium.

Authors:  Muriel Derrien; Elaine E Vaughan; Caroline M Plugge; Willem M de Vos
Journal:  Int J Syst Evol Microbiol       Date:  2004-09       Impact factor: 2.747

9.  Gut microbiota in patients with Parkinson's disease in southern China.

Authors:  Aiqun Lin; Wenxia Zheng; Yan He; Wenli Tang; Xiaobo Wei; Rongni He; Wei Huang; Yuying Su; Yaowei Huang; Hongwei Zhou; Huifang Xie
Journal:  Parkinsonism Relat Disord       Date:  2018-08       Impact factor: 4.891

Review 10.  Mitochondrial Dysfunction in Parkinson's Disease.

Authors:  Hyo Eun Moon; Sun Ha Paek
Journal:  Exp Neurobiol       Date:  2015-06-08       Impact factor: 3.261

View more
  18 in total

Review 1.  The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic.

Authors:  Ai Huey Tan; Shen Yang Lim; Anthony E Lang
Journal:  Nat Rev Neurol       Date:  2022-06-24       Impact factor: 44.711

2.  Daily Inclusion of Resistant Starch-Containing Potatoes in a Dietary Guidelines for Americans Dietary Pattern Does Not Adversely Affect Cardiometabolic Risk or Intestinal Permeability in Adults with Metabolic Syndrome: A Randomized Controlled Trial.

Authors:  Sisi Cao; Emily L Shaw; William R Quarles; Geoffrey Y Sasaki; Priyankar Dey; Joanna K Hodges; Avinash Pokala; Min Zeng; Richard S Bruno
Journal:  Nutrients       Date:  2022-04-08       Impact factor: 6.706

Review 3.  Environmental triggers of Parkinson's disease - Implications of the Braak and dual-hit hypotheses.

Authors:  Honglei Chen; Keran Wang; Filip Scheperjans; Bryan Killinger
Journal:  Neurobiol Dis       Date:  2021-12-23       Impact factor: 7.046

4.  FLUID study: study protocol for an open-label, single-centre pilot study to investigate the efFect of Lemborexant on sleep management in Japanese sUbjects aged 50 years and older with Insomnia Disorder.

Authors:  Ippei Okada; Kunihiro Iwamoto; Seiko Miyata; Akihiro Fujimoto; Masaki Tanaka; Manabu Amano; Nao Matsuyama; Toshiaki Taoka; Shinji Naganawa; Norio Ozaki
Journal:  BMJ Open       Date:  2021-11-26       Impact factor: 2.692

5.  Assessing the effect of interaction between C-reactive protein and gut microbiome on the risks of anxiety and depression.

Authors:  Yujing Chen; Peilin Meng; Shiqiang Cheng; Yumeng Jia; Yan Wen; Xuena Yang; Yao Yao; Chuyu Pan; Chun'e Li; Huijie Zhang; Jingxi Zhang; Zhen Zhang; Feng Zhang
Journal:  Mol Brain       Date:  2021-09-04       Impact factor: 4.041

6.  Intestinal Collinsella may mitigate infection and exacerbation of COVID-19 by producing ursodeoxycholate.

Authors:  Masaaki Hirayama; Hiroshi Nishiwaki; Tomonari Hamaguchi; Mikako Ito; Jun Ueyama; Tetsuya Maeda; Kenichi Kashihara; Yoshio Tsuboi; Kinji Ohno
Journal:  PLoS One       Date:  2021-11-23       Impact factor: 3.240

7.  Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease.

Authors:  Szu-Ju Chen; Chieh-Chang Chen; Hsin-Yu Liao; Ya-Ting Lin; Yu-Wei Wu; Jyh-Ming Liou; Ming-Shiang Wu; Ching-Hua Kuo; Chin-Hsien Lin
Journal:  Neurology       Date:  2022-01-07       Impact factor: 11.800

Review 8.  Regulation by Different Types of Chaperones of Amyloid Transformation of Proteins Involved in the Development of Neurodegenerative Diseases.

Authors:  Vladimir I Muronetz; Sofia S Kudryavtseva; Evgeniia V Leisi; Lidia P Kurochkina; Kseniya V Barinova; Elena V Schmalhausen
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

Review 9.  New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.

Authors:  Marina Lorente-Picón; Ariadna Laguna
Journal:  Biomolecules       Date:  2021-03-15

Review 10.  The Gut-Brain Axis and Its Relation to Parkinson's Disease: A Review.

Authors:  Emily M Klann; Upuli Dissanayake; Anjela Gurrala; Matthew Farrer; Aparna Wagle Shukla; Adolfo Ramirez-Zamora; Volker Mai; Vinata Vedam-Mai
Journal:  Front Aging Neurosci       Date:  2022-01-07       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.